Tocqueville Asset Management L.P. Purchases New Position in United Therapeutics Corporation $UTHR

Key Points

• Tocqueville Asset Management purchased 71,878 shares of United Therapeutics in the second quarter, worth approximately $38.9 million, giving it a 0.17% stake. Institutional investors and hedge funds collectively own 94.08% of the company.
• Analysts remain broadly positive, with 11 Buy ratings and two Holds producing a consensus “Moderate Buy” rating and an average price target of $646.
• United Therapeutics exceeded quarterly EPS expectations, reporting $7.27 versus the $6.86 estimate, although revenue fell 1.9% year over year to $783.3 million. Company insiders sold 434,275 shares worth about $235.4 million over the past 90 days.

Tocqueville Asset Management L.P. purchased a new stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 71,878 shares of the biotechnology company's stock, valued at approximately $38,946,000. Tocqueville Asset Management L.P. owned 0.17% of United Therapeutics at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in shares of United Therapeutics in the 2nd quarter valued at $2,868,735,000. Wellington Management Group LLP increased its position in shares of United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company's stock worth $1,189,617,000 after purchasing an additional 1,042,711 shares in the last quarter. Norges Bank acquired a new stake in shares of United Therapeutics during the 4th quarter worth about $293,418,000. Avoro Capital Advisors LLC lifted its holdings in United Therapeutics by 17.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company's stock valued at $1,269,803,000 after purchasing an additional 383,838 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its holdings in United Therapeutics by 75.1% during the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company's stock valued at $387,801,000 after purchasing an additional 341,383 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

UTHR has been the topic of several research analyst reports. JPMorgan Chase & Co. upped their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an "overweight" rating in a research note on Thursday, July 23rd. TD Cowen reissued a "buy" rating on shares of United Therapeutics in a report on Thursday, May 21st. Wells Fargo & Company upgraded United Therapeutics from an "equal weight" rating to an "overweight" rating and increased their price target for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Royal Bank Of Canada cut their price objective on United Therapeutics from $704.00 to $677.00 and set an "outperform" rating for the company in a research report on Thursday, August 6th. Finally, Weiss Ratings raised United Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a research note on Thursday, August 13th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, United Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $646.00.

United Therapeutics Trading Up 2.1%

Shares of NASDAQ UTHR opened at $529.14 on Thursday. United Therapeutics Corporation has a 1-year low of $302.19 and a 1-year high of $609.35. The company has a market cap of $22.69 billion, a PE ratio of 18.93, a P/E/G ratio of 1.75 and a beta of 0.59. The company has a 50-day moving average of $534.23 and a two-hundred day moving average of $537.17.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same period in the prior year, the business earned $6.41 earnings per share. United Therapeutics's quarterly revenue was down 1.9% on a year-over-year basis. As a group, equities research analysts forecast that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

Insider Activity at United Therapeutics

In other news, CFO James Edgemond sold 10,000 shares of the business's stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $546.28, for a total transaction of $5,462,800.00. Following the completion of the sale, the chief financial officer owned 18,876 shares in the company, valued at $10,311,581.28. The trade was a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of the company's stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $547.61, for a total value of $5,202,295.00. Following the transaction, the chief executive officer directly owned 40,513 shares in the company, valued at $22,185,323.93. This trade represents a 19.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 434,275 shares of company stock valued at $235,371,678 in the last 90 days. 8.60% of the stock is currently owned by corporate insiders.

United Therapeutics Company Profile

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source